MOTIF BIO PLC/S (NASDAQ:MTFB) Trading Down 11.5%
MOTIF BIO PLC/S (NASDAQ:MTFB)’s stock price was down 11.5% during mid-day trading on Monday . The company traded as low as $0.22 and last traded at $0.23, approximately 1,473,401 shares were traded during trading. An increase of 349% from the average daily volume of 327,934 shares. The stock had previously closed at $0.26.
A number of research analysts have recently issued reports on MTFB shares. Zacks Investment Research raised MOTIF BIO PLC/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. ValuEngine raised MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Northland Securities set a $5.00 target price on MOTIF BIO PLC/S and gave the stock a “buy” rating in a research note on Monday, July 15th.
The company has a market capitalization of $3.20 million, a P/E ratio of -3.08 and a beta of -0.01. The company has a 50 day moving average of $0.55 and a 200-day moving average of $1.17.
About MOTIF BIO PLC/S (NASDAQ:MTFB)
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
See Also: Is the QQQ ETF safe?
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.